title: Eplerenone reduces arterial thrombosis in diabetic rats.
abstract: BACKGROUND
  Clinical studies demonstrated the benefits of eplerenone (EPL) in reduction of cardiovascular events in diabetic patients. Since acute myocardial infarction (AMI) and stroke are related to acute intravascular thrombosis, we postulate that the beneficial effects of EPL may result from its antithrombotic action.
  
  
  METHODS
  Streptozotocin (STZ)-induced diabetic rats were treated with EPL (100 mg/kg/day) for 10 days. Thrombosis in the carotid artery was stimulated electrically.
  
  
  RESULTS
  Thrombosis development was enhanced in STZ-induced diabetic rats as compared to normoglycaemic controls. EPL caused prolongation of the time to artery occlusion, reduction in the incidence of occlusion and decrease in thrombus weight. Changes in the thrombi structure and the inhibition of hypertrophy of the tunica media in the artery wall were also observed. EPL caused reduction in tissue factor, plasminogen activator inhibitor type 1 and interleukin-1β plasma levels.
  
  
  CONCLUSIONS
  Our study demonstrated the antithrombotic effect of EPL manifested by a decrease in the dynamics of thrombus formation and changes in its structure. The changes in thrombosis process were accompanied by antihaemostatic, profibrinolytic and anti-inflammatory effects. The aldosterone blockade with EPL seems to be an additional pharmacological strategy for the prevention and treatment of thrombotic disorders in diabetes.
authors.affiliation: Department of Biopharmacy, Medical University of Białystok, Poland.
authors.forename: Agnieszka
authors.initials: A
authors.lastname: Zakrzeska
authors.affiliation: Department of Biopharmacy, Medical University of Białystok, Poland.
authors.forename: Anna
authors.initials: A
authors.lastname: Gromotowicz-Popławska
authors.affiliation: Department of Medical Biochemistry, Medical University of Łódź, Poland.
authors.forename: Janusz
authors.initials: J
authors.lastname: Szemraj
authors.affiliation: Department of Biopharmacy, Medical University of Białystok, Poland.
authors.forename: Piotr
authors.initials: P
authors.lastname: Szoka
authors.affiliation: Department of Biopharmacy, Medical University of Białystok, Poland.
authors.forename: Wioleta
authors.initials: W
authors.lastname: Kisiel
authors.affiliation: Department of Biopharmacy, Medical University of Białystok, Poland.
authors.forename: Tomasz
authors.initials: T
authors.lastname: Purta
authors.affiliation: Department of Histology and Cytophysiology, Medical University of Białystok, Poland.
authors.forename: Irena
authors.initials: I
authors.lastname: Kasacka
authors.affiliation: Department of Biopharmacy, Medical University of Białystok, Poland chabewa@poczta.onet.pl.
authors.forename: Ewa
authors.initials: E
authors.lastname: Chabielska
mesh_terms: D000818:Animals; D002339:Carotid Arteries / Q000187:drug effects / Q000503:physiopathology; D003921:Diabetes Mellitus, Experimental / Q000150:complications* / Q000188:drug therapy* / Q000503:physiopathology; D000077545:Eplerenone; D006487:Hemostasis / Q000187:drug effects; D007378:Interleukins / Q000378:metabolism; D008297:Male; D017208:Rats, Wistar; D012039:Regional Blood Flow / Q000187:drug effects; D013148:Spironolactone / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D013927:Thrombosis / Q000097:blood / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D014654:Vascular Patency / Q000187:drug effects
chemical_list: D007378:Interleukins; D013148:Spironolactone; D000077545:Eplerenone
keywords: Eplerenone; aldosterone; arterial thrombosis; diabetes; rats